Hubbry Logo
Mood disorderMood disorderMain
Open search
Mood disorder
Community hub
Mood disorder
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Mood disorder
Mood disorder
Mood disorder
View on Wikipedia
from Wikipedia

Mood disorder
Other namesmental disorder
A depressive man standing by a country pond in the pouring rain
SpecialtyNeuropsychiatry
TypesBipolar disorder, cyclothymia, disruptive mood dysregulation disorder, dysthymia, major depressive disorder, premenstrual dysphoric disorder, seasonal affective disorder
CausesFamily history, previous diagnosis of a mood disorder, trauma, stress or major life changes in the case of depression, physical illness or use of certain medications. Depression has been linked to major diseases such as cancer, diabetes, Parkinson's disease and heart disease, Brain structure and function in the case of bipolar disorder.[1]
MedicationAntidepressants, mood stabilizers, antipsychotics[1]

A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder[2] where the main underlying characteristic is a disturbance in the person's mood.[3] The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

Mood disorders fall into seven groups,[2] including; abnormally elevated mood, such as mania or hypomania; depressed mood, of which the best-known and most researched is major depressive disorder (MDD) (alternatively known as clinical depression, unipolar depression, or major depression); and moods which cycle between mania and depression, known as bipolar disorder (BD) (formerly known as manic depression). There are several subtypes of depressive disorders or psychiatric syndromes featuring less severe symptoms such as dysthymic disorder (similar to MDD, but longer lasting and more persistent, though often milder) and cyclothymic disorder (similar to but milder than BD).[4]

In some cases, more than one mood disorder can be present in an individual, like bipolar disorder and depressive disorder.[5] Mood disorders may also be substance induced, or occur in response to a medical condition.

English psychiatrist Henry Maudsley proposed an overarching category of affective disorder.[6] The term was then replaced by mood disorder, as the latter refers to the underlying or longitudinal emotional state,[7] whereas the former refers to the external expression observed by others.[3]

Classification

[edit]

Depressive disorders

[edit]
  • Major depressive disorder (MDD), commonly called major depression, unipolar depression, or clinical depression, wherein a person has one or more major depressive episodes. After a single episode, Major Depressive Disorder (single episode) would be diagnosed. After more than one episode, the diagnosis becomes Major Depressive Disorder (Recurrent). Depression without periods of mania is sometimes referred to as unipolar depression because the mood remains at the bottom "pole" and does not climb to the higher, manic "pole" as in bipolar disorder.[8]
Individuals with a major depressive episode or major depressive disorder are at increased risk for suicide. Seeking help and treatment from a health professional dramatically reduces the individual's risk for suicide. Studies have demonstrated that asking if a depressed friend or family member has thought of committing suicide is an effective way of identifying those at risk, and it does not "plant" the idea or increase an individual's risk for suicide in any way.[9] Epidemiological studies carried out in Europe suggest that, at this moment, roughly 8.5 percent of the world's population have a depressive disorder. No age group seems to be exempt from depression, and studies have found that depression appears in infants as young as 6 months old who have been separated from their mothers.[10] However, there may be differences between cultures in prevalence of MDD due to cultural influences that "challenge the definition and diagnosis of psychiatric disorders", as seen in a study by Parker et al. that researched MDD in Chinese individuals.[11] Depressive disorder (also known as depression) is a common mental disorder. It involves a depressed mood or loss of pleasure or interest in activities for long periods of time. Depression is different from regular mood changes and feelings about everyday life. It can affect all aspects of life. Depression can happen to anyone. People who have lived through abuse, severe losses, or other stressful events are more likely to develop depression.[12]
  • Depressive disorder is frequent in primary care and general hospital practice but is often undetected. Unrecognized depressive disorder may slow recovery and worsen prognosis in physical illness, therefore it is important that all doctors be able to recognize the condition, treat the less severe cases, and identify those requiring specialist care.[13]
Diagnosticians recognize several subtypes or course specifiers:
  • Atypical depression (AD) is characterized by mood reactivity (paradoxical anhedonia) and positivity,[clarification needed] significant weight gain or increased appetite ("comfort eating"), excessive sleep or somnolence (hypersomnia), a sensation of heaviness in limbs known as leaden paralysis, and significant social impairment as a consequence of hypersensitivity to perceived interpersonal rejection.[14] Difficulties in measuring this subtype have led to questions of its validity and prevalence.[15]
  • Psychotic major depression (PMD), or simply psychotic depression, is the term for a major depressive episode, in particular of melancholic nature, wherein the patient experiences psychotic symptoms such as delusions or, less commonly, hallucinations. These are most commonly mood-congruent (content coincident with depressive themes).[17]
  • Postpartum depression (PPD) is listed as a course specifier in DSM-IV-TR; it refers to the intense, sustained and sometimes disabling depression experienced by women after giving birth. Postpartum depression, which affects 10–15% of women, typically sets in within three months of labor, and lasts as long as three months.[19] It is quite common for women to experience a short-term feeling of tiredness and sadness in the first few weeks after giving birth; however, postpartum depression is different because it can cause significant hardship and impaired functioning at home, work, or school as well as, possibly, difficulty in relationships with family members, spouses, or friends, or even problems bonding with the newborn.[20] In the treatment of postpartum major depressive disorders and other unipolar depressions in women who are breastfeeding, nortriptyline, paroxetine (Paxil), and sertraline (Zoloft) are in general considered to be the preferred medications.[21] Women with personal or family histories of mood disorders are at particularly high risk of developing postpartum depression.[22]
  • Seasonal affective disorder (SAD), also known as "winter depression" or "winter blues", is a specifier. Some people have a seasonal pattern, with depressive episodes coming on in the autumn or winter, and resolving in spring. The diagnosis is made if at least two episodes have occurred in colder months with none at other times over a two-year period or longer.[25] It is commonly hypothesised that people who live at higher latitudes tend to have less sunlight exposure in the winter and therefore experience higher rates of SAD, but the epidemiological support for this proposition is not strong (and latitude is not the only determinant of the amount of sunlight reaching the eyes in winter). It is said that this disorder can be treated by light therapy.[26] SAD is also more prevalent in people who are younger and typically affects more females than males.[27]
  • Dysthymia is a condition related to unipolar depression, where the same physical and cognitive problems are evident, but they are not as severe and tend to last longer (usually at least 2 years).[28] The treatment of dysthymia is largely the same as for major depression, including antidepressant medications and psychotherapy.[9]
  • Double depression can be defined as a fairly depressed mood (dysthymia) that lasts for at least two years and is punctuated by periods of major depression.[28]
  • Unspecified Depressive Disorder is designated by the code 311 for depressive disorders. In the DSM-5, Unspecified Depressive Disorder encompasses symptoms that are characteristic of depressive disorders and cause significant impairment in functioning, but do not meet the criteria for the diagnosis of any specified depressive disorders. In the DSM-IV, this was called Depressive Disorder Not Otherwise Specified.
  • Depressive personality disorder (DPD) is a controversial psychiatric diagnosis that denotes a personality disorder with depressive features. Originally included in the DSM-II, depressive personality disorder was removed from the DSM-III and DSM-III-R.[29] Recently, it has been reconsidered for reinstatement as a diagnosis. Depressive personality disorder is currently described in Appendix B in the DSM-IV-TR as worthy of further study.
  • Recurrent brief depression (RBD), distinguished from major depressive disorder primarily by differences in duration. People with RBD have depressive episodes about once per month, with individual episodes lasting less than two weeks and typically less than 2–3 days. Diagnosis of RBD requires that the episodes occur over the span of at least one year and, in female patients, independently of the menstrual cycle.[30] People with clinical depression can develop RBD, and vice versa and both illnesses have similar risks.[31][clarification needed]
  • Minor depressive disorder, or simply minor depression, which refers to a depression that does not meet full criteria for major depression but in which at least two symptoms are present for two weeks.[32]

Bipolar disorders

[edit]
  • Bipolar disorder (BD) (also called "manic depression" or "manic-depressive disorder"), an unstable emotional condition characterized by cycles of abnormal, persistent high mood (mania) and low mood (depression),[33] which was formerly known as "manic depression" (and in some cases rapid cycling, mixed states, and psychotic symptoms).[34] Subtypes include:
  • Bipolar I is distinguished by the presence or history of one or more manic episodes or mixed episodes with or without major depressive episodes. A depressive episode is not required for the diagnosis of Bipolar I Disorder, but depressive episodes are usually part of the course of the illness.
  • Bipolar II consisting of recurrent intermittent hypomanic and depressive episodes or mixed episodes.
  • Cyclothymia is a form of bipolar disorder, consisting of recurrent hypomanic and dysthymic episodes, but no full manic episodes or full major depressive episodes.
  • Bipolar disorder not otherwise specified (BD-NOS), sometimes called "sub-threshold" bipolar, indicates that the patient has some symptoms in the bipolar spectrum (e.g., manic and depressive symptoms) but does not fully qualify for any of the three formal bipolar DSM-IV diagnoses mentioned above.
It is estimated that roughly 1% of the adult population has bipolar I, a further 1% has bipolar II or cyclothymia, and somewhere between 2% and 5% percent have "sub-threshold" forms of bipolar disorder. Furthermore, the possibility of getting bipolar disorder when one parent is diagnosed with it is 15–30%. Risk, when both parents have it, is 50–75%. Also, while with bipolar siblings the risk is 15–25%, with identical twins it is about 70%.[35]

Substance-induced

[edit]

A mood disorder can be classified as substance-induced if its etiology can be traced to the direct physiologic effects of a psychoactive drug or other chemical substance, or if the development of the mood disorder occurred contemporaneously with substance intoxication or withdrawal. Also, an individual may have a mood disorder coexisting with a substance abuse disorder. Substance-induced mood disorders can have features of a manic, hypomanic, mixed, or depressive episode. Most substances can induce a variety of mood disorders. For example, stimulants such as amphetamine, methamphetamine, and cocaine can cause manic, hypomanic, mixed, and depressive episodes.[36][unreliable source?]

Alcohol-induced

[edit]

High rates of major depressive disorder occur in heavy drinkers and those with alcoholism. Controversy has previously surrounded whether those who abused alcohol and developed depression were self-medicating their pre-existing depression. Recent research has concluded that, while this may be true in some cases, alcohol misuse directly causes the development of depression in a significant number of heavy drinkers. Participants studied were also assessed during stressful events in their lives and measured on a Feeling Bad Scale. Likewise, they were also assessed on their affiliation with deviant peers, unemployment, and their partner's substance use and criminal offending.[37][38][39] High rates of suicide also occur in those who have alcohol-related problems.[40] It is usually possible to differentiate between alcohol-related depression and depression that is not related to alcohol intake by taking a careful history of the patient.[39][41][42] Depression and other mental health problems associated with alcohol misuse may be due to distortion of brain chemistry, as they tend to improve on their own after a period of abstinence.[43]

Benzodiazepine-induced

[edit]

Benzodiazepines, such as alprazolam, clonazepam, lorazepam and diazepam, can cause both depression and mania.[44]

Benzodiazepines are a class of medication commonly used to treat anxiety, panic attacks and insomnia, and are also commonly misused and abused. Those with anxiety, panic and sleep problems commonly have negative emotions and thoughts, depression, suicidal ideations, and often have comorbid depressive disorders. While the anxiolytic and hypnotic effects of benzodiazepines may disappear as tolerance develops, depression and impulsivity with high suicidal risk commonly persist.[45] These symptoms are "often interpreted as an exacerbation or as a natural evolution of previous disorders and the chronic use of sedatives is overlooked".[45] Benzodiazepines do not prevent the development of depression, can exacerbate preexisting depression, can cause depression in those with no history of it, and can lead to suicide attempts.[45][46][47][48][49] Risk factors for suicide and suicide attempts while using benzodiazepines include high dose prescriptions (even in those not misusing the medications), benzodiazepine intoxication, and underlying depression.[44][50][51]

The long-term use of benzodiazepines may have a similar effect on the brain as alcohol, and are also implicated in depression.[52] As with alcohol, the effects of benzodiazepine on neurochemistry, such as decreased levels of serotonin and norepinephrine, are believed to be responsible for the increased depression.[53][54][55][56][57][58] Additionally, benzodiazepines can indirectly worsen mood by worsening sleep (i.e., benzodiazepine-induced sleep disorder). Like alcohol, benzodiazepines can put people to sleep but, while asleep, they disrupt sleep architecture: decreasing sleep time, delaying time to REM sleep, and decreasing deep sleep (the most restorative part of sleep for both energy and mood).[59][60][61] Just as some antidepressants can cause or worsen anxiety in some patients due to being activating, benzodiazepines can cause or worsen depression due to being a central nervous system depressant—worsening thinking, concentration and problem solving (i.e., benzodiazepine-induced neurocognitive disorder).[44] However, unlike antidepressants, in which the activating effects usually improve with continued treatment, benzodiazepine-induced depression is unlikely to improve until after stopping the medication.[60][61]

In a long-term follow-up study of patients dependent on benzodiazepines, it was found that 10 people (20%) had taken drug overdoses while on chronic benzodiazepine medication despite only two people ever having had any pre-existing depressive disorder. A year after a gradual withdrawal program, no patients had taken any further overdoses.[48]

Just as with intoxication and chronic use, benzodiazepine withdrawal can also cause depression.[62][63][64] While benzodiazepine-induced depressive disorder may be exacerbated immediately after discontinuation of benzodiazepines, evidence suggests that mood significantly improves after the acute withdrawal period to levels better than during use.[45] Depression resulting from withdrawal from benzodiazepines usually subsides after a few months but in some cases may persist for 6–12 months.[65][66]

Due to another medical condition

[edit]

"Mood disorder due to a general medical condition" is used to describe manic or depressive episodes which occur secondary to a medical condition.[67] There are many medical conditions that can trigger mood episodes, including neurological disorders (e.g. dementias), hearing loss and associated disorders (e.g. tinnitus or hyperacusis), metabolic disorders (e.g. electrolyte disturbances), gastrointestinal diseases (e.g. cirrhosis), endocrine disease (e.g. thyroid abnormalities), cardiovascular disease (e.g. heart attack), pulmonary disease (e.g. chronic obstructive pulmonary disease), cancer, autoimmune diseases (e.g. multiple sclerosis),[67] and pregnancy.

Not otherwise specified

[edit]
See also: DSM-IV codes

Mood disorder not otherwise specified (MD-NOS) is a mood disorder that is impairing but does not fit in with any of the other officially specified diagnoses. In the DSM-IV MD-NOS is described as "any mood disorder that does not meet the criteria for a specific disorder."[68] MD-NOS is not used as a clinical description but as a statistical concept for filing purposes.[69] The diagnosis of MD-NOS does not exist in the DSM-5, however the diagnoses of unspecified depressive disorder and unspecified bipolar disorder are in the DSM-5.[70]

Most cases of MD-NOS represent hybrids between mood and anxiety disorders, such as mixed anxiety-depressive disorder or atypical depression.[69] An example of an instance of MD-NOS is being in minor depression frequently during various intervals, such as once every month or once in three days.[68] There is a risk for MD-NOS not to get noticed, and for that reason not to get treated.[71]

Causes

[edit]

Meta-analyses show that high scores on the personality domain neuroticism are a strong predictor for the development of mood disorders.[72]

A depressed mood is a predictable response to certain types of life occurrences, such as loss of status, divorce, or death of a child or spouse. These are events that signal a loss of reproductive ability or potential, or that did so in humans' ancestral environment. A depressed mood can be seen as an adaptive response, in the sense that it causes an individual to turn away from the earlier (and reproductively unsuccessful) modes of behavior.[citation needed]

A depressed mood is common during illnesses, such as influenza. It has been argued that this is an evolved mechanism that assists the individual in recovering by limiting their physical activity.[73] The occurrence of low-level depression during the winter months, or seasonal affective disorder, may have been adaptive in the past, by limiting physical activity at times when food was scarce.[73] It is argued that humans have retained the instinct to experience low mood during the winter months, even if the availability of food is no longer determined by the weather.[73]

Much of what is known about the genetic influence of clinical depression is based upon research that has been done with identical twins. Identical twins have exactly the same genetic code. It has been found that when one identical twin becomes depressed the other will also develop clinical depression approximately 76% of the time. When identical twins are raised apart from each other, they will both become depressed about 67% of the time. Because both twins become depressed at such a high rate, the implication is that there is a strong genetic influence. If it happened that when one twin becomes clinically depressed the other always develops depression, then clinical depression would likely be entirely genetic.[74]

Bipolar disorder is also considered a mood disorder and it is hypothesized that it might be caused by mitochondrial dysfunction.[75][76][77]

Sex differences

[edit]

Mood disorders, specifically stress-related mood disorders such as anxiety and depression, have been shown to have differing rates of diagnosis based on sex. In the United States, women are two times more likely than men to be diagnosed with a stress-related mood disorder.[78][79] Underlying these sex differences, studies have shown a dysregulation of stress-responsive neuroendocrine function causing an increase in the likelihood of developing these affective disorders.[80] Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis could provide potential insight into how these sex differences arise. Neuropeptide corticotropin-releasing factor (CRF) is released from the paraventricular nucleus (PVN) of the hypothalamus, stimulating adrenocorticotropic hormone (ACTH) release into the blood stream. From here ACTH triggers the release of glucocorticoids such as cortisol from the adrenal cortex. Cortisol, known as the main stress hormone, creates a negative feedback loop back to the hypothalamus to deactivate the stress response.[81] When a constant stressor is present, the HPA axis remains overactivated and cortisol is constantly produced. This chronic stress is associated with sustained CRF release, resulting in the increased production of anxiety- and depressive-like behaviors and serving as a potential mechanism for differences in prevalence between men and women.[78]

Diagnosis

[edit]

DSM-5

[edit]

The DSM-5, released in May 2013, separates the mood disorder chapter from the DSM-IV-TR into two sections: Depressive and related disorders and bipolar and related disorders. Bipolar disorders fall in between depressive disorders and schizophrenia spectrum and related disorders "in recognition of their place as a bridge between the two diagnostic classes in terms of symptomatology, family history and genetics" (Ref. 1, p 123).[44] Bipolar disorders underwent a few changes in the DSM-5, most notably the addition of more specific symptomology related to hypomanic and mixed manic states. Depressive disorders underwent the most changes, the addition of three new disorders: disruptive mood dysregulation disorder, persistent depressive disorder (previously dysthymia), and premenstrual dysphoric disorder (previously in appendix B, the section for disorders needing further research). Disruptive mood dysregulation disorder is meant as a diagnosis for children and adolescents who would normally be diagnosed with bipolar disorder as a way to limit the bipolar diagnosis in this age cohort. Major depressive disorder (MDD) also underwent a notable change, in that the bereavement clause has been removed. Those previously exempt from a diagnosis of MDD due to bereavement are now candidates for the MDD diagnosis.[82]

Treatment

[edit]

There are different types of treatments available for mood disorders, such as therapy and medications. Behaviour therapy, cognitive behaviour therapy and interpersonal therapy have all shown to be potentially beneficial in depression.[83][84] Major depressive disorder medications usually include antidepressants; a combination of antidepressants and cognitive behavioral therapy has shown to be more effective than one treatment alone.[85] Bipolar disorder medications can consist of antipsychotics, mood stabilizers, anticonvulsants[86] and/or lithium. Lithium specifically has been proven to reduce suicide and all causes of mortality in people with mood disorders.[87] If mitochondrial dysfunction or mitochondrial diseases are the cause of mood disorders like bipolar disorder,[75] then it has been hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.[88] In determining treatment, there are many types of depression scales that are used. One of the depression scales is a self-report scale called Beck Depression Inventory (BDI). Another scale is the Hamilton Depression Rating Scale (HAMD). HAMD is a clinical rating scale in which the patient is rated based on clinician observation.[89] The Center for Epidemiologic Studies Depression Scale (CES-D) is a scale for depression symptoms that applies to the general population. This scale is typically used in research and not for self-reports. The PHQ-9 which stands for Patient-Health Questionnaire-9 questions, is a self-report as well. Finally, the Mood Disorder Questionnaire (MDQ) evaluates bipolar disorder.[90]

Epidemiology

[edit]

According to a substantial number of epidemiology studies conducted, women are twice as likely to develop certain mood disorders, such as major depression. Although there is an equal number of men and women diagnosed with bipolar II disorder, women have a slightly higher frequency of the disorder.[91]

In 2011, mood disorders were the most common reason for hospitalization among children aged 1–17 years in the United States, with approximately 112,000 stays.[92] Mood disorders were top principal diagnosis for Medicaid super-utilizers in the United States in 2012.[93] Further, a study of 18 states found that mood disorders accounted for the highest number of hospital readmissions among Medicaid patients and the uninsured, with 41,600 Medicaid patients and 12,200 uninsured patients being readmitted within 30 days of their index stay—a readmission rate of 19.8 per 100 admissions and 12.7 per 100 admissions, respectively.[94] In 2012, mood and other behavioral health disorders were the most common diagnoses for Medicaid-covered and uninsured hospital stays in the United States (6.1% of Medicaid stays and 5.2% of uninsured stays).[95]

A study conducted in 1988 to 1994 amongst young American adults involved a selection of demographic and health characteristics. A population-based sample of 8,602 men and women ages 17–39 years participated. Lifetime prevalence were estimated based on six mood measures:

  • major depressive episode (MDE) 8.6%,
  • major depressive disorder with severity (MDE-s) 7.7%,
  • dysthymia 6.2%,
  • MDE-s with dysthymia 3.4%,
  • any bipolar disorder 1.6%, and
  • any mood disorder 11.5%.[96]

Research

[edit]
See also: List of investigational antidepressants

Kay Redfield Jamison and others have explored the possible links between mood disorders – especially bipolar disorder – and creativity. It has been proposed that a "ruminating personality type may contribute to both [mood disorders] and art."[97]

Jane Collingwood notes an Oregon State University study that:

looked at the occupational status of a large group of typical patients and found that 'those with bipolar illness appear to be disproportionately concentrated in the most creative occupational category.' They also found that the likelihood of 'engaging in creative activities on the job' is significantly higher for bipolar than nonbipolar workers.[98]

In Liz Paterek's article "Bipolar Disorder and the Creative Mind" she wrote:

Memory and creativity are related to mania. Clinical studies have shown that those in a manic state will rhyme, find synonyms, and use alliteration more than controls. This mental fluidity could contribute to an increase in creativity. Moreover, mania creates increases in productivity and energy. Those in a manic state are more emotionally sensitive and show less inhibition about attitudes, which could create greater expression. Studies performed at Harvard looked into the amount of original thinking in solving creative tasks. Bipolar individuals, whose disorder was not severe, tended to show greater degrees of creativity.[99]

The relationship between depression and creativity appears to be especially strong among poets.[100][101]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Mood disorder

View on Grokipedia
from Grokipedia
Mood disorders, also known as affective disorders, are a group of conditions characterized by significant and persistent disruptions in a person's emotional state, primarily affecting their mood and leading to severe lows such as depression or highs such as or . These disorders interfere with daily functioning, relationships, and overall , often involving symptoms like persistent , loss of interest in activities, excessive energy, or that last for weeks or months. The two major categories of mood disorders are depressive disorders and bipolar disorders, each encompassing several subtypes. Depressive disorders include , which involves intense feelings of sadness and hopelessness, and persistent depressive disorder (), marked by chronic low mood lasting at least two years. Bipolar disorders feature alternating episodes of depression and or , with subtypes such as bipolar I (including full manic episodes), bipolar II (hypomanic episodes), and cyclothymic disorder (milder, chronic fluctuations). Other notable types include , primarily affecting children with severe , and substance-induced mood disorder, triggered by drug or alcohol use. In the United States, approximately 9.7% of U.S. adults had any mood disorder in the past year as of , with prevalence higher among females (11.6%) than males (7.7%). Globally, the 12-month of mood disorders is approximately 5.4% among adults, contributing significantly to the burden of mental illness. Risk factors include , family history, stressful life events, , and biological factors such as imbalances in chemicals like serotonin and norepinephrine. Environmental influences, including chronic medical conditions like heart or disorders, can also exacerbate vulnerability. Diagnosis typically involves clinical assessment based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), evaluating symptom duration, severity, and impact on functioning. Treatment often combines psychotherapy, such as cognitive-behavioral therapy, with medications like antidepressants or mood stabilizers, and lifestyle interventions to manage symptoms and prevent recurrence. Early intervention is crucial, as untreated mood disorders increase risks of suicide, substance abuse, and physical health complications.

Introduction

Definition and Scope

Mood disorders constitute a category of disorders characterized by persistent disturbances in an individual's mood, which fundamentally impact emotional regulation, cognitive processes, and behavioral patterns. These conditions involve sustained deviations from typical emotional states, ranging from profound sadness and loss of interest in unipolar depressive forms to alternating episodes of depression and elevated mood in bipolar forms. The scope of mood disorders primarily includes unipolar depressive disorders, such as (MDD), and bipolar and related disorders, such as and , as outlined in classification systems like the DSM-5-TR. In contrast to normal mood fluctuations, which are brief and adaptive responses to everyday events without causing substantial disruption, mood disorders feature prolonged and intense emotional alterations that result in clinically significant impairment in daily functioning, such as difficulties in work, relationships, or . They differ from adjustment disorders, which represent temporary emotional and behavioral reactions to identifiable stressors and generally remit within six months of the stressor's cessation or resolution. Mood disorders exert a profound influence on , ranking among the leading causes of worldwide. According to the , depression—the most prevalent mood disorder—is the primary cause of globally, affecting over 300 million people and contributing significantly to years lived with . Data from the indicate that in 2019, depressive disorders alone accounted for 46.8 million (95% UI 33.0–63.8) disability-adjusted life years (DALYs) lost, representing 37.3% (32.3–43.0%) of all DALYs attributable to mental disorders, while added further burden through approximately 9.8 million (95% UI 6.2–14.4) DALYs. As of the 2021 GBD update, the burden has increased further, particularly for depressive disorders, due to the .

Historical Development

The concept of mood disorders traces its roots to , where (c. 400 BCE) described as a condition arising from an excess of black bile, one of the four humors believed to regulate bodily and emotional states, manifesting as persistent fear and sadness without . This humoral theory framed mood disturbances as imbalances in bodily fluids, influencing medical thought for centuries and distinguishing from other forms of madness. In the , German psychiatrist advanced a more systematic classification, distinguishing manic-depressive illness—characterized by cyclic episodes of mania and depression—from (later ) in his 1899 textbook Psychiatrie, emphasizing course and prognosis over symptoms alone. Kraepelin's dichotomous model laid the foundation for modern affective disorder by highlighting the recurrent, non-deteriorating nature of manic-depressive illness. Early 20th-century developments included Adolf Meyer's psychobiological approach in the 1910s, which viewed mental disorders like mood illnesses as reactions to life stresses within a holistic mind-body framework, shifting focus from purely organic causes to integrated personality dynamics. A pivotal pharmacological milestone occurred in 1949 when Australian psychiatrist discovered lithium's efficacy in treating manic excitement in bipolar patients, marking the first specific intervention for mood stabilization and spurring research into biological underpinnings. The 1952 Diagnostic and Statistical Manual of Mental Disorders (DSM-I) classified manic-depressive reactions, including psychotic depressive reactions, under affective reactions, reflecting psychoanalytic influences and a reactional model of psychiatric illness. The 1960s-1970s anti-psychiatry movement, led by figures like and , critiqued psychiatric labeling of mood disorders as socially constructed controls, influencing reforms in and diagnostic practices. The 1980 DSM-III revolutionized classification by introducing the "mood disorders" category, encompassing major depression and with explicit, atheoretical criteria to enhance reliability, moving away from psychoanalytic etiology. Post-1980s, evidence-based paradigms emerged through advances in , revealing structural and functional alterations in mood disorders, and , with linkage studies identifying familial risk factors, solidifying a neurobiological understanding.

Classification

Depressive Disorders

Depressive disorders encompass a group of unipolar mood conditions characterized by persistent and pervasive low mood without the presence of manic or hypomanic episodes that define bipolar disorders. These disorders are classified in the DSM-5-TR under distinct categories based on duration, severity, and specific features, focusing on disruptions in emotional regulation that impair daily functioning. Major depressive disorder (MDD) is defined as one or more major depressive episodes, each involving recurrent periods of severe or lasting at least two weeks, accompanied by at least four additional symptoms such as significant weight changes, sleep disturbances, or retardation, , feelings of worthlessness, diminished concentration, or recurrent thoughts of death. Episodes must represent a change from previous functioning and not be attributable to substances or another medical condition. MDD often recurs, with lifetime estimated at 5-17% in the general population. Persistent depressive disorder, formerly known as , involves chronic low-grade depression characterized by depressed mood for most of the day, more days than not, lasting at least two years in adults (or one year in children and adolescents). This condition may include additional symptoms like poor appetite or , or , low energy, low , poor concentration, or hopelessness, but requires fewer symptoms than for . It consolidates previous DSM-IV categories of chronic and dysthymia, reflecting its overlapping but milder, protracted nature. Other specified subtypes include , primarily affecting children aged 6 to 18, marked by severe recurrent temper outbursts and chronic irritability not better explained by . involves severe depressive symptoms, such as marked affective lability, irritability, or depressed mood, that occur in the majority of menstrual cycles during the final week before menses onset and remit within days of . Depressive disorder due to another medical condition features a prominent and persistent depressed mood directly attributable to physiological effects of a medical illness, such as or . Remission in depressive disorders is specified as partial if symptoms of a previous episode persist but do not meet full criteria, or full if no significant signs or symptoms have been present for at least two months. Recurrence rates for MDD are high, with 50-85% of individuals experiencing further episodes within five years following initial recovery. Unlike in DSM-IV, does not automatically exclude a of MDD during bereavement; instead, if full criteria are met beyond two months post-loss or with severe impairment, it may be diagnosed, emphasizing clinical judgment on context and duration. In contrast to bipolar depression, depressive disorders lack any history of manic or hypomanic episodes, maintaining a unipolar course without elevated mood phases. Bipolar and related disorders encompass a spectrum of conditions characterized by alternating episodes of elevated or irritable mood and depressive states, distinguishing them from unipolar depressive disorders by the presence of mood elevation phases. These disorders are defined in the DSM-5-TR, published in 2022 by the American Psychiatric Association, which introduced refinements to diagnostic criteria to better differentiate them from other psychotic or mood conditions. The spectrum includes Bipolar I disorder, Bipolar II disorder, cyclothymic disorder, and other specified bipolar and related disorders, with specifiers such as rapid cycling—defined as four or more mood episodes in a 12-month period—applied to highlight patterns of frequent shifts. Bipolar I disorder requires at least one manic episode, which consists of a distinct period of abnormally and persistently elevated, expansive, or irritable mood and increased energy or goal-directed activity lasting at least one week (or any duration if hospitalization is required), accompanied by at least three additional symptoms such as , decreased need for , or excessive involvement in risky activities, leading to marked impairment in social or occupational functioning. This manic episode must not be attributable to the physiological effects of a substance or another medical condition and is not better explained by , , or , as clarified in the DSM-5-TR updates. Major depressive episodes, meeting criteria for significant and persistent low mood with associated symptoms, frequently occur but are not required for diagnosis. Bipolar II disorder is diagnosed when an individual experiences at least one hypomanic episode and at least one , but never a full . A hypomanic episode involves a distinct period of elevated, expansive, or irritable mood and increased energy lasting at least four consecutive days, with at least three similar symptoms to but without the marked impairment, , or need for hospitalization that defines . The DSM-5-TR specifies that the hypomanic episode must cause a clear change in functioning that is observable by others, yet it remains distinct from in severity. Cyclothymic disorder involves a chronic pattern of numerous periods of hypomanic symptoms and depressive symptoms over at least two years (one year for children and adolescents), where these symptoms do not meet full criteria for hypomanic or major depressive episodes. During this period, the symptoms must be present for at least half the time, with no symptom-free intervals exceeding two months, and the condition cannot be better explained by another disorder or substance use. This fluctuating course distinguishes as a milder, more persistent form within the bipolar spectrum. Other specified bipolar and related disorder captures presentations that cause significant distress or impairment but fall short of full criteria for Bipolar I, II, or , such as a lasting only two to three days accompanied by a major depressive episode, or a without a history of major depression. The DSM-5-TR also includes examples like short-duration (less than two years) or with insufficient symptoms, emphasizing clinical utility in specifying these variants.

Other Mood Disorders

Other mood disorders encompass mood disturbances that do not align with the primary categories of depressive or bipolar disorders, often arising as secondary effects from external factors or atypical presentations. These include substance/medication-induced mood disorders, mood disorders due to another condition, and other specified or unspecified mood disorders, which serve as diagnostic categories for cases requiring further specification or not fully meeting established criteria. Substance/medication-induced mood disorder is characterized by a prominent and persistent disturbance in mood—such as a depressive or manic episode—that is attributable to the physiological effects of a substance or , with onset occurring during or soon after intoxication, withdrawal, or exposure. For instance, use may precipitate manic symptoms, while alcohol withdrawal can lead to depressive states, highlighting the direct causal link to the substance's impact on . Diagnosis requires evidence that the mood symptoms exceed those typically associated with the substance and are not better explained by an independent mood disorder. Mood disorder due to another medical condition involves mood disturbances directly resulting from a physiological issue, where the mood changes are a secondary manifestation rather than the primary . Examples include depressive symptoms arising from , which disrupts thyroid regulation affecting serotonin pathways, or manic features following a impacting function. The disorder is diagnosed only after confirming the medical condition through clinical evaluation and ruling out independent primary mood disorders, ensuring the mood symptoms are etiologically linked to the underlying . Other specified and unspecified mood disorders provide residual categories for clinically significant mood presentations that do not meet full criteria for depressive, bipolar, or related disorders but cause distress or impairment. The other specified category allows clinicians to denote specific reasons, such as recurrent brief depression—characterized by short depressive episodes lasting less than two weeks recurring frequently—while unspecified is used when further details are unavailable or insufficient for specification. These categories facilitate comprehensive assessment without forcing ill-fitting diagnoses and are placed within both depressive and bipolar sections in DSM-5-TR due to the absence of a unified mood disorders grouping. In the classification, effective from 2019, these secondary and residual mood disorders are integrated into the broader chapter on mood disorders, alongside primary types, under a framework that emphasizes known physiological causes for induced forms and allows for other specified or unspecified designations to capture atypical or incomplete presentations. This reorganization aligns mood disorders with reporting standards, promoting consistency in clinical and epidemiological applications while prioritizing the exclusion of primary mood etiologies before assigning these categories.

Signs and Symptoms

Core Symptoms of Depression

The core symptoms of depression, as outlined in major diagnostic frameworks, encompass a range of emotional, cognitive, and physical disturbances that significantly impair daily functioning. These symptoms are central to (MDD), requiring at least five symptoms present for a substantial portion of nearly every day during a two-week period, with at least one being depressed mood or loss of or pleasure (anhedonia). This cluster distinguishes depressive episodes from normal sadness, emphasizing persistence and severity that cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. Emotional symptoms form the affective core of depression, characterized by persistent feelings of sadness, hopelessness, excessive guilt, and emotional numbness. Individuals often report a pervasive of emptiness or despair that permeates their emotional , sometimes described as a "flat" or detached affect where even minor positive events fail to elicit joy. , the marked loss of interest or pleasure in previously enjoyable activities, is particularly hallmark and affects motivation across domains like hobbies, social interactions, and work. These emotional manifestations contrast sharply with the elevated mood seen in manic episodes, highlighting depression's inward withdrawal. Cognitive symptoms involve disruptions in thinking and , including difficulty concentrating, indecisiveness, and recurrent thoughts of death or . Concentration issues may manifest as an inability to read, follow conversations, or complete tasks, often leading to rumination on negative self-perceptions. , ranging from passive wishes to die to active planning, is common in MDD, affecting approximately 30-50% of individuals during depressive episodes, underscoring its prevalence as a critical . Physical and vegetative symptoms reflect the disorder's impact on bodily functions, such as significant changes in or weight (either increase or decrease), sleep disturbances including or , and profound or loss of energy. Psychomotor changes, observable as agitation (restlessness) or retardation (slowed movements and speech), further illustrate the somatic burden. Somatic complaints, like unexplained , headaches, or gastrointestinal distress without identifiable medical causes, are common and often lead individuals to seek physical rather than care initially. For , symptoms must endure for at least two weeks and represent a change from previous functioning, excluding those better explained by substance use, medical conditions, or bereavement. Severity is gauged by the number and intensity of symptoms, with mild cases involving minimal impairment and severe cases potentially including psychotic features, though the core remains the same.

Symptoms of and

Mania and hypomania represent elevated mood states in bipolar and related disorders, characterized by distinct periods of abnormally and persistently elevated, expansive, or irritable mood accompanied by increased energy or activity. These episodes contrast with the low energy and sadness of depressive phases, often leading to heightened productivity or impulsivity depending on severity. The core feature is an elevated mood, which may manifest as , , or expansiveness, persisting for at least four consecutive days in or one week (or any duration if hospitalization is required) in full . During these periods, individuals often exhibit increased energy and goal-directed activity, including inflated or , where they may feel exceptionally capable or destined for greatness. A hallmark is the decreased need for , such as feeling rested after only three hours per night without subsequent . Other cognitive symptoms include talkativeness or pressured speech, and or flight of ideas, where the mind jumps rapidly between topics. Behavioral manifestations further define these episodes, with excessive involvement in high-risk activities that carry potential for painful consequences, such as unrestrained spending sprees, sexual indiscretions, or reckless business decisions. Distractibility is common, as attention is easily drawn to irrelevant stimuli, alongside or hyperactivity in pursuing goals, whether social, occupational, or sexual. These symptoms must represent a noticeable change from the individual's baseline and not be attributable to substances or medical conditions. Severity distinguishes from : hypomanic episodes cause no marked impairment in social or occupational functioning and do not necessitate hospitalization, often appearing as a period of enhanced mood without severe disruption. In contrast, manic episodes involve marked impairment, such as inability to fulfill role obligations, or require hospitalization to prevent harm to self or others due to the intensity of symptoms. In severe , psychotic features—such as delusions of grandeur or hallucinations—occur in approximately 50-70% of cases, exacerbating the risk of dangerous behaviors.

Atypical and Mixed Presentations

represents a subtype of characterized by distinct symptom patterns that differ from typical melancholic depression. Key features include mood reactivity, where an individual's mood improves in response to positive events, alongside increased or hyperphagia, significant , , a sensation of leaden in the arms or legs, and heightened sensitivity to interpersonal rejection or criticism. These symptoms often lead to a more chronic course and may respond preferentially to certain inhibitors compared to antidepressants. The DSM-5-TR introduces a mixed features specifier applicable to depressive or manic episodes, indicating the presence of subthreshold symptoms from the opposite pole, such as three or more manic/hypomanic symptoms during a major depressive episode (e.g., elevated mood, , or co-occurring with profound sadness and hopelessness). This specifier highlights the overlap between depressive and bipolar spectrum disorders, with mixed states manifesting as dysphoric agitation or amid low mood, which complicates and . Notably, the presence of mixed features significantly elevates risk, with studies indicating increased odds (up to 3- to 5-fold) compared to non-mixed depressive episodes. Rapid cycling in is defined as four or more mood episodes—meeting criteria for , , or major depression—within a 12-month period, separated by at least two months of remission or a switch to an opposite polarity episode. This pattern affects approximately 10-20% of individuals with over their lifetime and is associated with a more severe, treatment-resistant course, including higher rates of hospitalization. It occurs more frequently in women, comprising up to 70% of rapid-cycling cases in some cohorts, and is often linked to comorbid thyroid dysfunction, such as , which may exacerbate mood instability through disruptions in regulation. Catatonia can emerge as a rare but severe presentation within mood disorders, particularly in severe depression or bipolar , featuring psychomotor disturbances such as immobility, , mutism, negativism (resistance to instructions), or excessive purposeless motor activity like stereotypies. Catatonia occurs in approximately 5-20% of acute psychiatric inpatients, with mood disorders accounting for a significant proportion of cases, particularly in severe depressive or manic episodes (up to 20% in some studies). These symptoms reflect a profound disruption in motor and behavioral regulation, often requiring urgent intervention, with (ECT) demonstrating high efficacy in resolving catatonic features when benzodiazepines prove insufficient. Cultural factors influence the expression of mood disorder symptoms, with non-Western populations, particularly in Asian and Latin American contexts, more frequently presenting with somatic complaints—such as , , or gastrointestinal distress—rather than overt psychological descriptors like or guilt. This tendency arises from cultural norms emphasizing physical over emotional distress, stigma around , and explanatory models attributing mood changes to bodily imbalances, which can delay recognition of underlying depressive or bipolar pathology in diverse settings.

Etiology

Genetic and Biological Factors

Mood disorders, including (MDD) and , exhibit significant genetic contributions, with heritability estimates derived from twin and family studies indicating a moderate to high inherited component. For MDD, twin studies consistently report heritability rates of approximately 40-50%, reflecting the influence of genetic factors alongside environmental interactions. In contrast, shows higher heritability, estimated at 70-80% based on concordance rates in monozygotic twins, which reach up to 67% compared to much lower rates in dizygotic twins. These estimates underscore the polygenic nature of mood disorders, where multiple genetic variants contribute to vulnerability rather than a single mendelian locus. Recent large-scale genome-wide association studies (GWAS) as of 2025 have expanded this understanding, identifying 697 genetic associations for depression and 298 regions for , further highlighting the complex genetic architecture. Genome-wide association studies (GWAS) have identified specific genetic loci associated with increased risk. For , variants in the CACNA1C , which encodes a , and the ODZ4 (also known as TENM4), involved in neural development, have been replicated in large-scale analyses from the , highlighting their role in neuronal signaling and connectivity. In MDD, the short of the promoter polymorphism () has been reported to interact with environmental stress to elevate depression risk in some studies; however, meta-analyses show mixed results, with evidence of heightened susceptibility under adverse conditions in earlier research but conflicting findings in more recent analyses questioning the interaction's robustness. Family patterns further support genetic transmission, with first-degree relatives of affected individuals facing a 2-4 times higher risk of developing mood disorders compared to the general . Additionally, some bipolar pedigrees demonstrate , characterized by earlier age of onset and potentially increased severity in successive generations, though evidence is mixed and may reflect ascertainment biases rather than purely genetic mechanisms such as intergenerational epigenetic or repeat expansion effects. Beyond , biological factors such as endocrine dysregulation contribute to mood disorder vulnerability. The hypothalamic-pituitary-adrenal (HPA) axis, central to stress response, is hyperactive in many cases, with elevated levels observed in about 50% of individuals with MDD, leading to chronic physiological stress. disruptions also play a key role, often linked to variants in clock genes like PER2, which regulates daily biological cycles and has been associated with mood instability in both MDD and . These physiological alterations amplify genetic predispositions, contributing to the onset and course of mood disorders.

Environmental and Psychosocial Factors

Environmental and psychosocial factors play a significant role in the onset and exacerbation of mood disorders, often interacting with underlying vulnerabilities to trigger depressive or manic episodes. These external influences, including early life adversities and ongoing stressors, can disrupt emotional regulation and increase susceptibility to conditions like (MDD) and . Research highlights how modifiable social and environmental elements contribute to the diathesis-stress model, where stressors precipitate illness in predisposed individuals. Adverse childhood experiences (ACEs), such as trauma, abuse, neglect, or household dysfunction, are strongly linked to an elevated risk of developing MDD in adulthood, with individuals experiencing ACEs showing approximately 2.5 times higher odds of youth-onset depression compared to those without such histories. This association demonstrates a dose-response relationship, where the cumulative number of ACEs correlates with greater risk; for instance, adults reporting four or more ACEs are 4.6 times more likely to experience depression in the previous year than those with none. These early adversities can alter stress response systems and interpersonal functioning, perpetuating vulnerability to mood dysregulation over time. Major life events, including bereavement, divorce, or financial loss, frequently precede the onset of mood episodes, aligning with the stress-vulnerability model proposed by Paykel in the 1970s, which posits that such stressors interact with predispositions to initiate illness. Studies indicate that severe life events trigger about 50% of first depressive episodes, underscoring their role as proximal precipitants rather than distant causes. In recurrent cases, the impact may diminish, but initial episodes often align closely with these acute stressors. Socioeconomic factors like and are associated with 1.5 to 2 times higher prevalence of depression, as lower levels correlate with increased psychological distress and limited access to resources. For example, individuals in the lowest brackets within communities exhibit 1.5 times greater rates of depressive symptoms, while carries an of about 1.86 for maintaining depressive states. These conditions compound stress through chronic insecurity and reduced coping capacity. Deficits in social support, such as isolation or perceived lack of emotional backing, heighten the risk of relapse in mood disorders by fostering feelings of disconnection and helplessness. Prospective research shows that poorer perceived social support predicts worse depression outcomes, with low support linked to up to 1.62 times higher odds of persistent symptoms or recurrence. Strong social networks, conversely, buffer against relapse by providing validation and practical aid during vulnerable periods. Cultural influences, particularly stigma in collectivist societies, contribute to delayed help-seeking for mood disorders, as societal emphasis on and amplifies around mental illness. In such contexts, misconceptions portray depression as personal weakness or affliction, leading to avoidance of professional care and reliance on informal networks, which can worsen outcomes. efforts in these cultures aim to reduce stigma to encourage timely intervention.

Pathophysiology

Neurochemical Imbalances

The monoamine hypothesis posits that mood disorders arise from imbalances in monoamine neurotransmitters, including serotonin (5-HT), norepinephrine, and dopamine, which are crucial for regulating mood, arousal, and reward processing. In major depressive disorder (MDD), deficiencies in these neurotransmitters are implicated, with reduced serotonin activity observed in unmedicated patients through decreased plasma tryptophan levels (Hedge’s g = 0.84) and lowered serotonin transporter binding in brain imaging studies. In bipolar disorder, the hypothesis extends to excesses of these monoamines during manic episodes, potentially leading to heightened arousal and euphoria, as supported by early formulations linking catecholamine surplus to mania. Beyond monoamines, dysregulation of excitatory and inhibitory neurotransmitters contributes to mood instability. In bipolar disorder, elevated glutamate levels have been detected in postmortem frontal cortex samples from affected individuals, suggesting hyperglutamatergic activity that may drive manic symptoms through excessive synaptic excitation. This involves N-methyl-D-aspartate (NMDA) receptors, which play a key role in synaptic plasticity and are altered in bipolar disorder, with mood stabilizers modulating their expression to restore balance. Concurrently, imbalances in gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter, may fail to counteract this excitation, exacerbating mood swings, though direct CSF evidence remains limited. Reduced plasma , the precursor to serotonin, can be diverted via the , particularly under inflammatory conditions, leading to neurotoxic metabolites and further serotonin depletion in MDD. Inflammatory processes further disrupt neurochemical in mood disorders, with pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) elevated in peripheral blood of patients with MDD and . Meta-analyses indicate these elevations occur in a substantial proportion of cases, correlating with symptom severity and contributing to the "sickness behavior" model, where cytokines mimic depressive symptoms like fatigue and by activating brain immune pathways. As of 2025, evidence supports an inflammatory subtype of major depression with distinct pathophysiological features. This inflammatory milieu can indirectly suppress monoamine synthesis and , perpetuating mood dysregulation. Neuroplasticity deficits, particularly involving (BDNF), underlie chronic mood disturbances by impairing hippocampal . Reduced BDNF levels in the hippocampus of depressed individuals hinder neuron survival and synaptic remodeling, with meta-analyses showing lower peripheral BDNF correlating with depression severity and duration. This reduction is linked to stress-induced suppression of BDNF expression, limiting adaptive responses to emotional challenges. Evidence from antidepressant mechanisms reinforces these imbalances; selective serotonin reuptake inhibitors (SSRIs) enhance synaptic serotonin availability by blocking the serotonin transporter (SERT), which indirectly upregulates BDNF and promotes over weeks of treatment.

Brain Structure and Function

In individuals with (MDD), (MRI) studies have consistently demonstrated hippocampal volume reductions of approximately 4-8% as of 2024, with meta-analyses indicating that this is more pronounced in patients with multiple depressive episodes or longer illness duration. These volumetric changes are thought to reflect cumulative stress-related rather than a preexisting , as evidenced by correlations between smaller hippocampal size and the number of prior depressive episodes in longitudinal MRI data from the early . Structural alterations extend to the , where hypoactivity in the (DLPFC) impairs such as cognitive control and during depressive states. Concurrently, the exhibits hyperactivity in response to emotional stimuli, contributing to heightened negative affect and biased emotional processing, as observed in functional MRI (fMRI) tasks involving fear-related cues. In , alterations in the ventral , a key region in the brain's reward circuitry, disrupt reward processing; this manifests as blunted striatal responses during depressive phases, underlying , and elevated activity during manic or hypomanic episodes, which may drive excessive reward-seeking behaviors. Functional connectivity abnormalities further characterize mood disorders, with dysregulation of the (DMN)—comprising regions like the medial and posterior cingulate—linked to persistent rumination and self-referential negative thinking in MDD, as shown in resting-state fMRI studies. Additionally, fMRI evidence reveals a disconnect between limbic structures (such as the ) and prefrontal regulatory areas, reducing top-down modulation of emotional responses and exacerbating affective instability across mood disorders. White matter hyperintensities (WMHs), indicative of microvascular damage, are elevated in late-onset depression and are associated with vascular risk factors like and cerebral small vessel disease, supporting the vascular depression . These lesions, often located in periventricular and deep tracts, correlate with poorer treatment response and greater relapse risk in older adults with depression.

Diagnosis

Diagnostic Criteria

The diagnostic criteria for mood disorders are primarily outlined in two major classification systems: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), published by the in 2022, and the , 11th Revision (), issued by the in 2019. In DSM-5-TR, (MDD) requires at least one characterized by five or more symptoms present during the same 2-week period, representing a change from previous functioning, with at least one symptom being either depressed mood most of the day nearly every day or markedly diminished interest or pleasure in all or almost all activities. Additional symptoms may include significant weight loss or gain, or , or retardation, fatigue, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, or recurrent thoughts of death or . The episode must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning and must not be attributable to the physiological effects of a substance or another medical condition. For , the diagnosis hinges on the occurrence of at least one manic episode, defined as a distinct period of abnormally and persistently elevated, expansive, or irritable mood and increased goal-directed activity or energy lasting at least 1 week (or any duration if hospitalization is required), accompanied by at least three additional symptoms such as , decreased need for sleep, talkativeness, flight of ideas, distractibility, increased goal-directed activity, or excessive involvement in risky activities. This manic episode must not be better explained by or superimposed on or other psychotic disorders. The criteria for a single episode depressive disorder similarly require the presence of a depressive episode, marked by depressed mood, loss of interest or pleasure, and reduced or increased fatigability, plus at least two additional symptoms from a list including disturbed , reduced concentration, low self-confidence, excessive self-reproach or guilt, suicidal thoughts or acts, psychomotor disturbance, and significant or appetite change, persisting for several weeks (typically at least two) and causing marked impairment in personal functioning. For bipolar type I disorder, mandates at least one manic episode with elevated mood and increased activity or , accompanied by at least three other symptoms (e.g., increased talkativeness, decreased need for , ), lasting at least one week and causing significant disruption in personal functioning, without requiring a depressive episode for diagnosis. Bipolar type II disorder requires at least two recurrent depressive episodes and at least one hypomanic episode, with the latter involving milder symptoms of elevated mood and increased lasting at least several days but not meeting full criteria. Unlike DSM-5-TR, explicitly incorporates functional impairment as a core diagnostic element across mood disorders to distinguish pathological states from normal variations in mood. Both systems include specifiers to refine diagnoses. In DSM-5-TR, common specifiers for mood episodes include "with anxious distress" (marked by tension, restlessness, or worry during the episode), "with psychotic features" (presence of delusions or hallucinations congruent or incongruent with mood), and "with peripartum onset" (onset during pregnancy or within four weeks postpartum). A notable change from DSM-5, retained in DSM-5-TR, is the removal of the bereavement exclusion, allowing MDD diagnosis during or shortly after bereavement if full criteria are met, with guidance to differentiate it from normal grief based on symptom severity and persistence. Age-specific criteria address developmental variations. (DMDD), applicable to children aged 6 through 18 years, targets chronic severe and frequent temper outbursts (at least three times per week for at least one year, with no symptom-free periods longer than three months), with onset before age 10, to prevent overdiagnosis of in youth exhibiting persistent rather than episodic . Diagnosis in both frameworks requires clinician judgment to account for cultural norms, ensuring symptoms are interpreted within the individual's sociocultural context rather than pathologizing normative expressions of distress, and to exclude cases attributable to substances or medical conditions through history and evaluation. ICD-11 further emphasizes cultural context by integrating considerations of how societal expectations influence symptom presentation and impairment.

Differential Diagnosis and Assessment

The assessment of mood disorders involves a multifaceted approach to confirm the and exclude alternative explanations, emphasizing structured tools for symptom evaluation and systematic exclusion of medical and psychiatric mimics. Structured clinical interviews, such as the Structured Clinical Interview for (SCID-5), serve as the gold standard for probing symptoms of mood disorders like and , offering high reliability in diagnostic categorization with test-retest agreement exceeding 80% for most modules. Similarly, the Mini-International Neuropsychiatric Interview (MINI) provides a brief, validated alternative for systematic assessment of mood episodes, demonstrating strong concordance with longer interviews in identifying depressive and manic symptoms across diverse populations. These interviews facilitate a comprehensive review of symptom duration, severity, and impairment, ensuring alignment with diagnostic thresholds while minimizing clinician bias. Self-report scales complement clinical interviews by quantifying symptom intensity. The Patient Health Questionnaire-9 (PHQ-9) is widely used to gauge depressive symptoms, where scores of 10 or higher indicate moderate depression with 88% for . For manic or hypomanic states, the Young Mania Rating Scale (YMRS), an 11-item clinician-administered tool, rates symptom severity on a 0-60 scale, with scores above 20 suggesting significant and aiding in tracking response to interventions. These instruments are integrated into routine evaluations to provide objective metrics, though they require clinical correlation to avoid over-reliance on self-reported data. A thorough and laboratory testing are essential to rule out organic contributors to mood symptoms, as medical conditions can underlie a notable proportion of cases presenting as mood disorders. Common tests include function panels to exclude or , which can mimic depressive or manic presentations; complete blood counts to detect ; and serum levels, as deficiency is common among individuals with depression and may exacerbate symptoms. Additional screening for imbalances, substance use, or neurological issues via if indicated helps delineate primary mood pathology from secondary effects. Differential diagnosis requires distinguishing mood disorders from overlapping conditions, as symptoms like low mood or irritability can occur across entities. Anxiety disorders, comorbid in approximately 50% of mood disorder cases, are differentiated by predominant and autonomic rather than pervasive or . is considered when psychotic features persist beyond mood episodes, with mood-congruent hallucinations favoring over primary . Personality disorders, such as , present with rapid mood lability tied to interpersonal triggers, unlike the cyclical patterns in . Neurological conditions like or must be excluded through cognitive testing and history, as they can produce affective changes without true mood cycling. Longitudinal assessment enhances diagnostic accuracy by capturing the episodic nature of mood disorders, particularly in bipolar presentations. Mood charting tools, such as daily self-monitoring apps or the Life-Chart Method, track symptom fluctuations over weeks to months, revealing cycling patterns that single assessments may miss and improving detection of hypomania. Collateral history from members is crucial for corroborating episode frequency and severity, especially when insight is impaired. Post-COVID-19 adaptations have incorporated for mood disorder assessments, maintaining diagnostic validity through virtual structured interviews and scales. Validation studies indicate good concordance between and in-person evaluations for mood diagnoses, supporting its role in ongoing monitoring amid access barriers.

Management

Pharmacological Treatments

Pharmacological treatments for mood disorders primarily target depressive episodes in (MDD) and manic or mixed episodes in , aiming to restore neurochemical balance and stabilize mood through targeted modulation. These interventions are typically first-line for moderate to severe cases, with selection guided by symptom profile, comorbidities, and patient-specific factors such as side effect tolerance. Common classes include antidepressants for unipolar depression, mood stabilizers and antipsychotics for , and emerging agents for treatment-resistant cases. Antidepressants are the cornerstone for treating depressive symptoms in mood disorders, particularly MDD. Selective serotonin reuptake inhibitors (SSRIs), such as at doses of 20-40 mg/day, are often first-line due to their favorable and tolerability profile, with response rates around 60% in clinical trials. Serotonin-norepinephrine reuptake inhibitors (SNRIs) like (starting at 75 mg/day, titrated to 225 mg/day) provide similar benefits, particularly for patients with prominent anxiety or pain symptoms, achieving comparable response rates to SSRIs. Atypical antidepressants, such as bupropion (150-300 mg/day), offer an alternative for those with sexual side effects from SSRIs or comorbid , with in preventing . However, all antidepressants carry an FDA black-box warning for increased suicidality risk in children, adolescents, and young adults, necessitating close monitoring during the initial treatment phase. For bipolar disorder, mood stabilizers are essential to prevent manic, hypomanic, or depressive relapses. Lithium remains a gold standard, administered to maintain serum levels of 0.6-1.2 mEq/L, which has been shown to reduce suicide risk by up to 80% in long-term use among patients with bipolar disorder. Anticonvulsants like valproate (plasma levels 50-125 μg/mL) and lamotrigine (up to 200 mg/day) are effective alternatives, particularly for rapid cycling or mixed episodes; valproate acts via GABA enhancement and sodium channel blockade, while lamotrigine is especially useful for bipolar depression prophylaxis through glutamate modulation. These agents are often combined with antidepressants cautiously to avoid mood destabilization. Atypical antipsychotics play a key role in managing acute mania in bipolar disorder. Olanzapine (10-20 mg/day) and quetiapine (400-800 mg/day) are FDA-approved for this indication, with randomized trials showing response rates of approximately 50% within 3-6 weeks. Quetiapine is also effective for bipolar depression. Their mechanisms involve D2 and serotonin antagonism, providing rapid symptom control. For treatment-resistant depression (TRD), novel agents like and offer rapid relief. Intravenous (0.5 mg/kg over 40 minutes) exerts antidepressant effects via antagonism, yielding response rates of about 50% within hours, contrasting the weeks required for traditional s. , an intranasal S-enantiomer, is approved for TRD in combination with an oral , showing similar rapid onset and response rates in clinical studies. For , (oral, 14-day course) was approved in 2023, showing rapid remission rates of about 50% in trials. Side effects are a critical consideration in pharmacological management. Atypical antipsychotics like and are associated with significant in 20-30% of patients, often due to and serotonin receptor effects, increasing risks for . Mood stabilizers such as require regular monitoring for , including renal function tests every 6-12 months, as chronic use can lead to reduced in up to 20% of long-term users. Overall, treatment adherence is optimized through and periodic reassessment to balance efficacy and tolerability.

Psychotherapeutic Interventions

Psychotherapeutic interventions for mood disorders encompass structured, evidence-based talk therapies designed to alleviate symptoms, enhance skills, and prevent by addressing cognitive, emotional, and interpersonal factors. These approaches are typically delivered in 12-20 sessions by trained clinicians and are recommended as first-line treatments, particularly for mild to moderate (MDD) and as adjuncts to in . Unlike pharmacological options, psychotherapies emphasize skill-building and long-term resilience, with meta-analyses indicating comparable short-term efficacy to antidepressants but superior outcomes in sustaining remission. Cognitive-behavioral therapy (CBT) is a cornerstone intervention for mood disorders, particularly MDD, involving 12-16 weekly sessions that target maladaptive thought patterns and behaviors contributing to depressive symptoms. Through techniques such as and , patients learn to identify and challenge negative biases while increasing engagement in rewarding activities, which aids relapse prevention. In randomized controlled trials, CBT achieves remission rates of approximately 46-50% in adults with MDD, outperforming control conditions and demonstrating sustained benefits over 12-24 months. Interpersonal (IPT), a time-limited therapy spanning 12-16 sessions, focuses on resolving interpersonal conflicts and life transitions that exacerbate mood symptoms, making it particularly suitable for MDD in contexts like role disputes or . By improving communication and , IPT fosters emotional stability and has shown robust efficacy in reducing depressive episodes. For peripartum depression, IPT has shown recovery rates of approximately 40% in randomized trials, superior to control conditions, and is often preferred over medications due to its non-pharmacological nature and positive impact on maternal-infant bonding. In , family-focused therapy (FFT) integrates with family communication training over 21 sessions, educating participants on illness management, early warning signs of mood episodes, and problem-solving to reduce familial stress. This approach decreases mood episode recurrence by enhancing adherence and early intervention, with studies reporting up to 30% fewer relapses compared to individual therapy. FFT also lowers rehospitalization rates by approximately 40-50% over two years when combined with mood stabilizers, underscoring its role in stabilizing family dynamics. Dialectical behavior therapy (DBT), adapted for mood disorders with prominent emotion dysregulation, combines , distress tolerance, and emotion regulation skills in individual and group formats, typically over 6-12 months. Originally developed for , DBT addresses affective instability in bipolar or mixed mood presentations by teaching adaptive responses to intense emotions, leading to reduced symptom severity and improved functioning in transdiagnostic samples. Meta-analyses of randomized trials confirm that psychotherapies like CBT and IPT are equivalent to in acute symptom relief for depression but superior in preventing , with approximately 25-50% lower recurrence rates at one-year follow-up due to enduring skill acquisition. In , adjunctive therapies such as FFT further mitigate hospitalization risks when paired with medications, though combined approaches may optimize outcomes in severe cases.

Adjunctive and Lifestyle Approaches

Adjunctive and lifestyle approaches complement primary treatments for mood disorders by promoting behavioral and environmental changes that support symptom management and overall . These strategies emphasize self-managed practices accessible to individuals, focusing on , regulation, dietary patterns, techniques, and to enhance resilience against depressive and manic episodes. Evidence from systematic reviews indicates these interventions can reduce symptom severity and improve treatment outcomes when integrated into routine care. Regular aerobic exercise, such as walking or jogging for at least 150 minutes per week, has been shown to effectively reduce depressive symptoms in mood disorders, with meta-analyses reporting moderate effect sizes comparable to other active interventions. Mechanisms include the release of endorphins that elevate mood and promotion of neurogenesis in the hippocampus, which counters neuroplasticity deficits associated with depression. For instance, a network meta-analysis found walking, jogging, yoga, and strength training particularly beneficial, with standardized mean differences indicating clinically meaningful improvements in symptom scores. Sleep hygiene practices, including consistent bedtimes and wake times, contribute to mood stability in by regulating circadian rhythms disrupted in these conditions. Chronotherapy, such as timed light exposure, further supports this by advancing phases and accelerating responses, with clinical trials demonstrating remission rates up to 50% in acute episodes when combined with standard care. Systematic reviews confirm that improving quality through these methods leads to dose-dependent enhancements in , reducing depressive symptoms and relapse risk. Nutritional strategies, particularly omega-3 fatty acid supplementation at 1-2 grams of EPA daily, serve as adjuncts for mood disorders, with meta-analyses showing small but significant reductions in depressive symptoms across multiple trials. Higher adherence to a , rich in fruits, , and healthy fats, is inversely associated with depression risk, as evidenced by prospective cohort studies and reanalyses of observational data, potentially through effects. These approaches benefit approximately half of studied populations, though effects vary by baseline severity. Mindfulness-based stress reduction (MBSR) programs and practices help mitigate rumination, a core feature of depressive episodes in mood disorders, by fostering present-moment awareness and reducing emotional reactivity. Meta-analyses indicate these interventions yield small to moderate symptom reductions, with standardized mean differences of -0.69 for in short-term depression outcomes and similar effects for MBSR on anxiety and distress in mild cases. For example, mindfulness training mediates decreases in and rumination, leading to 20-30% improvements in self-reported mood scores in non-severe presentations. Peer-led support groups, such as those offered by the (NAMI), enhance medication adherence and illness management in mood disorders by providing experiential guidance and social connection. Studies show adjunctive increases treatment compliance by up to 25% through mechanisms like social comparison and emotional validation, reducing relapse rates in bipolar and depressive conditions. Participation fosters a of control, with randomized trials confirming higher adherence and perceived efficacy compared to unsupported programs.

Epidemiology

Prevalence and Distribution

Mood disorders, encompassing major depressive disorder (MDD) and bipolar disorder, affect a substantial portion of the global population. According to the World Health Organization, approximately 332 million people worldwide experienced depression in 2021, corresponding to a global prevalence of about 5.7% among adults. Bipolar disorder has a lower prevalence, with a point prevalence of approximately 0.5% globally (as of 2021), impacting around 37 million individuals. Lifetime risk for mood disorders varies by and setting, with women in high-income countries facing a 15-20% risk of developing MDD, compared to about 10% for men. In developed countries, is often higher in urban areas than rural ones, by a factor of approximately 1.5 times, reflecting environmental and differences. Age distribution shows that onset of mood disorders typically peaks between 20 and 30 years of age, though adolescent reaches around 10%. Geographic variations are notable; for instance, the age-standardized of depressive disorders is higher in the (around 5%) compared to (around 3.5%), as reported in the 2021. Recent Global Burden of Disease analyses indicate a continued rise in the burden of depressive disorders, with global stable but increasing due to (as of 2021 data). Recent trends indicate a 25% increase in the of depression and related mood disorders following the , attributed to heightened stressors such as isolation and economic uncertainty. Mood disorders exhibit notable sex differences in and associated risks. Women experience a 1.5- to 2-fold higher lifetime risk of (MDD) compared to men, with global annual rates of approximately 5.5% in women versus 3.2% in men. This disparity is partly attributed to hormonal fluctuations, such as variations in levels, which influence mood regulation and correlate with increased vulnerability during reproductive life stages. In contrast, men with MDD demonstrate higher rates of completion, at 4 to 5 times the rate of women, often linked to more lethal methods and lower help-seeking behaviors. Age and ethnicity significantly modulate the risk of mood disorders, with certain groups facing underdiagnosis or elevated burdens. Among older adults over 65 years, depression is prevalent but frequently underdiagnosed, affecting up to half of cases due to atypical presentations and stigma. Ethnic minorities, particularly Indigenous populations such as American Indians, show heightened risks for mood-related disorders, with rates approximately twice as high as the general population, compounded by and limited access to care. Socioeconomic status (SES) is a robust , where low SES doubles the likelihood of developing mood disorders through and resource scarcity. exacerbates this trend, with urban environments associated with a 15% rise in depression rates since 2010, driven by and environmental stressors rather than urbanization per se. Emerging trends highlight the role of modern environmental and technological factors in rising mood disorder rates. Excessive and use among correlates with a 30% increase in depression from 2010 to 2020, mediated by disruption and social comparison. Additionally, contributes to , a form of distress linked to mood disorders, particularly in young people experiencing heightened emotional responses to environmental threats. Protective factors, such as higher education and SES, mitigate mood disorder incidence by 20-30%, fostering resilience through enhanced coping skills and access to resources. , in particular, buffers against depressive symptoms by promoting psychosocial resources like and .

Prognosis

Short-Term and Long-Term Outcomes

Short-term outcomes for mood disorders, particularly (MDD), typically involve initial treatment responses within 8-12 weeks of first-line interventions like selective serotonin reuptake inhibitors. Approximately 50-70% of patients with MDD exhibit a significant symptom reduction, defined as at least a 50% decrease on standardized scales such as the Hamilton Depression Rating Scale. However, full remission, characterized by minimal residual symptoms and return to baseline functioning, occurs in only 30-40% of cases during this period, with non-response or partial response affecting the remainder and often necessitating treatment adjustments. Long-term trajectories reveal high rates of recurrence and chronicity across mood disorders. For MDD, recurrence affects about 50% of patients within 2 years following an initial episode, rising to 80% over a lifetime, influenced by factors such as episode severity and prior history. In , relapse rates reach up to 90% without ongoing maintenance therapy, with naturalistic studies reporting pooled recurrence of around 55% over 2 years in untreated or inadequately managed cases. Chronicity persists in 20-30% of MDD cases, particularly when comorbidities are present, leading to prolonged symptom duration exceeding 2 years. Predictors of recovery highlight the benefits of timely intervention; early treatment initiation is associated with improved remission rates in mood disorders by mitigating episode progression and neuroprogressive changes. Functional outcomes remain impaired long-term, with associated with rates of around 30-60%, reflecting disruptions in occupational stability. Quality-of-life measures, such as the , show substantially lower scores in domains for patients with compared to the general population, indicating persistent emotional and social deficits. Overall survival is also compromised, with mood disorders linked to a reduction in of 7-10 years, primarily due to indirect causes like and rather than the disorders themselves.

Complications and Comorbidities

Mood disorders are frequently accompanied by psychiatric comorbidities that exacerbate symptom severity and complicate treatment. Anxiety disorders co-occur with in approximately 50% of cases, with studies indicating that 50-75% of individuals with exhibit anxious depression features. Substance use disorders affect around 40-60% of individuals with over their lifetime, with alcohol and being the most commonly abused substances, contributing to poorer clinical outcomes. Eating disorders, such as binge-eating disorder, are comorbid in about 14-20% of patients with , often linked to mood instability and impulsive behaviors. Physical health complications are also prevalent among those with mood disorders, increasing overall morbidity. Individuals with depression face a 1.5- to 2-fold higher risk of compared to the general population, independent of traditional risk factors like or . This elevated risk stems from shared pathophysiological mechanisms, including and autonomic dysregulation. Diabetes mellitus, particularly type 2, shows a bidirectional association with mood disorders; depression can contribute to its development through sedentary lifestyle changes and medication side effects, while may worsen depressive symptoms. Suicide represents one of the most severe complications of mood disorders, with a lifetime of approximately 15% among affected individuals—roughly 15-20 times higher than in the general . In , around 60-70% of attempts occur during active depressive episodes, highlighting the critical need for vigilant monitoring during these periods. Social and functional impairments further compound the burden of mood disorders. In , rates are elevated, estimated at 35-45% or 2-3 times higher than in the general , often due to interpersonal conflicts arising from manic or depressive episodes. Occupationally, mood disorders, particularly depressive disorders, rank as the leading cause of worldwide according to the , affecting work productivity and leading to long-term unemployment in up to 50% of cases. Treatment for mood disorders can introduce iatrogenic complications, such as bone health issues from selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological option for depression. Long-term SSRI use is associated with reduced bone mineral density and an increased risk, potentially due to serotonin modulation of bone metabolism, affecting up to two-thirds of older adults on these medications.

Research Directions

Current Advances

Recent advancements in genetic research for mood disorders have focused on polygenic risk scores (PRS), which aggregate the effects of numerous common genetic variants to predict susceptibility. The Psychiatric Genomics Consortium (PGC) in 2023 contributed to GWAS efforts for bipolar disorder, enabling PRS that explain approximately 4-10% of the liability variance in independent cohorts. These scores have demonstrated utility in identifying individuals at elevated risk for bipolar disorder onset, particularly when combined with environmental factors, as shown in a 2023 longitudinal study of high-risk youth. In 2025, the National Institute of Mental Health (NIMH) released results from the largest-ever genome-wide association study of diverse populations with bipolar disorder, shedding new light on genetic architecture and enhancing PRS applicability across ancestries. Additionally, the Bipolar Disorder Discovery (BD²) initiative awarded $18 million in grants in October 2025 to advance research on bipolar biology, including causal mechanisms. In , (AI) integration with (fMRI) has advanced the identification of biomarkers for treatment response in mood disorders. A 2023 multi-study evaluation developed the neuromark framework, which uses on fMRI data to predict differential responses to antidepressants versus mood stabilizers with accuracies up to 95%, and up to 70% for responder versus non-responder prediction, highlighting disrupted connectivity in emotion-regulation networks, such as the , as key predictors. This approach offers a non-invasive tool to personalize for and . In January 2025, a global study led by the began mapping brain signatures of to transform understanding of structural alterations. Psychedelic-assisted therapies represent a promising frontier for (TRD) and comorbid conditions. Phase 2 trials of CYB003, a deuterated analog, demonstrated 75% remission rates at 4 months in TRD patients, leading to FDA Designation in March 2024 for its rapid and sustained effects; updated data from November 2024 showed 71% remission at 12 months after two doses. Similarly, MDMA-assisted has shown efficacy for PTSD with comorbid mood symptoms, with a 2023 phase 3 trial reporting significant reductions in depressive symptoms alongside 71% PTSD remission rates, attributed to enhanced emotional processing and . These therapies typically involve 2-3 guided sessions, with effects lasting 6-12 months in responders. Digital therapeutics have expanded access to (CBT) for mood disorders through AI-driven chatbots. Early randomized controlled trials (RCTs) of Woebot reported moderate reductions in depressive symptoms (e.g., ~3.5-point drop on over 2 weeks), with a 2025 review confirming significant reductions (p<0.001) across chatbots like Woebot for mild-to-moderate depression in adults and , though recent studies show mixed results with no superiority over other tools and adherence varying by design. These interventions emphasize , mood tracking, and , proving particularly effective for preventing escalation in subclinical cases. The has spurred longitudinal research revealing surges in mood disorders, especially among . Multiple cohort studies from 2020-2024 documented significant increases in depressive symptoms among adolescents, with global analyses indicating a ~25% rise in prevalence attributed to isolation, academic disruptions, and family stressors during peak lockdowns, underscoring the role of social determinants in exacerbating vulnerability and informing targeted interventions like school-based screenings.

Future Challenges and Innovations

One major challenge in managing mood disorders lies in the high rates of misdiagnosis, particularly the frequent classification of bipolar depression as unipolar , which can lead to inappropriate monotherapy and precipitate manic episodes. Treatment resistance further complicates outcomes, as untreated or inadequately managed depression often evolves into chronic forms, reducing response to standard pharmacotherapies. Comorbidities, including other psychiatric conditions and medical issues like , exacerbate diagnostic complexity and worsen prognosis. The integration of emerging technologies introduces additional hurdles, such as data privacy concerns under regulations like GDPR and HIPAA, which limit secure essential for advancing . Algorithmic biases in models, stemming from unrepresentative training datasets, risk perpetuating inequities in and treatment recommendations for diverse populations. Regulatory frameworks also lag behind, creating uncertainties in liability and validation for AI-driven tools in clinical settings. Innovations in precision medicine hold promise for overcoming these issues by leveraging biomarkers, such as alterations in inflammatory markers, , and metabolic pathways, to enable more accurate subtyping of mood disorders and personalized interventions. applications, including for analyzing patient narratives and digital phenotyping via wearables for real-time symptom monitoring, could facilitate early detection and predict treatment responses, minimizing trial-and-error prescribing; a 2025 review highlights integration with AI for mood disorders. Multimodal AI models integrating genetic, , and behavioral data are poised to refine risk stratification and tailor therapies. Novel therapeutic approaches, including neuromodulation techniques like (TMS) and (DBS), offer targeted relief for treatment-resistant cases by modulating neural circuits implicated in mood regulation. Psychedelic-assisted therapies, such as and , demonstrate rapid antidepressant effects in clinical trials, potentially reshaping paradigms for acute and maintenance treatment. These advancements, supported by large-scale biobanks and real-world data integration, aim to transition mood disorder care toward proactive, individualized strategies.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK558911/
  2. https://www.nimh.nih.gov/health/statistics/any-mood-disorder
  3. https://www.mayoclinic.org/diseases-conditions/mood-disorders/symptoms-causes/syc-20365057
  4. https://www.psychiatry.org/patients-families/bipolar-disorders/what-are-bipolar-disorders
  5. https://www.ncbi.nlm.nih.gov/books/NBK572966/
  6. https://academic.oup.com/ije/article/43/2/476/2901736
  7. https://www.mayoclinic.org/diseases-conditions/mental-illness/symptoms-causes/syc-20374968
  8. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
  9. https://www.mayoclinic.org/diseases-conditions/mood-disorders/diagnosis-treatment/drc-20365058
  10. https://www.nimh.nih.gov/health/topics/depression
  11. https://www.nimh.nih.gov/health/topics/bipolar-disorder
  12. https://www.psychiatry.org/patients-families/bipolar-disorders
  13. https://www.medicalnewstoday.com/articles/bipolar-disorder-vs-mood-swings
  14. https://my.clevelandclinic.org/health/diseases/21760-adjustment-disorder
  15. https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health
  16. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00395-3/fulltext
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4314947/
  18. https://embryo.asu.edu/pages/emil-kraepelin-1856-1926
  19. https://psychiatryonline.org/doi/10.1176/appi.ajp.2017.17070730
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4597240/
  21. https://psychiatryonline.org/doi/10.1176/appi.ajp.2011.11111697
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5039514/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC7684769/
  24. https://www.psychiatry.org/psychiatrists/practice/dsm/about-dsm/history-of-the-dsm
  25. https://www.nature.com/articles/s41398-020-0796-8
  26. https://www.nature.com/articles/npp2009104
  27. https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/dsm-5-tr-fact-sheets
  28. https://www.ncbi.nlm.nih.gov/books/NBK559078/
  29. https://www.psychiatry.org/getmedia/33fc7cdb-6fd8-46a7-9ff2-225ba7862f7f/APA-DSM5TR-MajorDepressiveDisorder.pdf
  30. https://www.ncbi.nlm.nih.gov/books/NBK541052/
  31. https://www.nimh.nih.gov/health/publications/disruptive-mood-dysregulation-disorder
  32. https://www.psychiatry.org/getmedia/e631c985-ee68-4be3-9941-0eb3b5b4d75d/APA-DSM5TR-DepressiveDisorderduetoAnotherMedicalCondition.pdf
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6061124/
  34. https://psychiatryonline.org/doi/10.1176/appi.focus.20200008
  35. https://www.psychiatry.org/File%2520Library/Psychiatrists/Practice/DSM/APA_DSM-5-Depression-Bereavement-Exclusion.pdf
  36. https://www.psychiatry.org/getmedia/98fd2c17-93f0-42cd-9f41-755d77b862a5/APA-DSM5TR-BipolarIandBipolarIIDisorders.pdf
  37. https://www.dbsalliance.org/education/bipolar-disorder/rapid-cycling-bipolar/
  38. https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t7/
  39. https://www.apa.org/monitor/2022/01/ce-bipolar-spectrum
  40. https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t23/
  41. https://www.ncbi.nlm.nih.gov/books/NBK558998/
  42. https://www.ncbi.nlm.nih.gov/books/NBK557877/
  43. https://www.merckmanuals.com/professional/psychiatric-disorders/mood-disorders/cyclothymic-disorder
  44. https://www.psychdb.com/bipolar/z-other-bipolar
  45. https://www.psychiatry.org/getmedia/ffc643b7-9382-4a29-a8c8-868dabcced10/APA-DSM5TR-OtherSpecifiedBipolarandRelatedDisorder.pdf
  46. https://www.psychiatry.org/getmedia/d2213583-2b81-41fe-90e5-3abbdf0f7d72/APA-DSM5TR-SubstanceMedicationInducedBipolarDisorder.pdf
  47. https://www.psychiatry.org/getmedia/4d6aab2f-87cf-4b22-afc4-8b9035076051/APA-DSM5TR-UnspecifiedMoodDisorder.pdf
  48. https://www.who.int/publications/i/item/9789240077263
  49. https://www.sciencedirect.com/science/article/pii/S0165032723010844
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3181769/
  51. https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t9/
  52. https://www.mayoclinic.org/diseases-conditions/bipolar-disorder/symptoms-causes/syc-20355955
  53. https://www.mdcalc.com/calc/10196/dsm-5-criteria-bipolar-disorder
  54. https://my.clevelandclinic.org/health/diseases/21774-hypomania
  55. https://www.cambridge.org/core/journals/psychological-medicine/article/lifetime-and-point-prevalence-of-psychotic-symptoms-in-adults-with-bipolar-disorders-a-systematic-review-and-metaanalysis/31492842FCD4D49E1FDE86B332F062AA
  56. https://pubmed.ncbi.nlm.nih.gov/11122970/
  57. https://pubmed.ncbi.nlm.nih.gov/11779285/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC5614762/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4116292/
  60. https://www.psychiatrictimes.com/view/mixed-features-suicide-and-adolescents-risk
  61. https://www.psychiatrist.com/jcp/rapid-cycling-bipolar-disorder-systematic-review/
  62. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.7.1273/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC6323302/
  64. https://www.ncbi.nlm.nih.gov/books/NBK430842/
  65. https://emedicine.medscape.com/article/1154851-overview
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC4473490/
  67. https://www.nejm.org/doi/full/10.1056/NEJM199910283411801
  68. https://www.psychiatrist.com/pdf/cultural-variations-in-the-clinical-presentation-of-depression-and-anxiety-implications-for-diagnosis-and-treatment-pdf/
  69. https://www.cell.com/cell/fulltext/S0092-8674(24)01415-6
  70. https://www.mountsinai.org/about/newsroom/2025/largest-genetic-study-of-bipolar-disorder-identifies-298-regions-of-the-genome-that-increase-risk-for-the-condition
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC3740203/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC5628077/
  73. https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.c.20009
  74. https://psychiatryonline.org/doi/10.1176/ajp.156.6.837
  75. https://www.sciencedirect.com/science/article/abs/pii/S0145213423000728
  76. https://www.sciencedirect.com/science/article/abs/pii/S0145213423000157
  77. https://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-0447.108.s418.13.x
  78. https://www.family-institute.org/sites/default/files/pdfs/csi_stroud_stress_depression.pdf
  79. https://www.science.org/doi/10.1126/science.aay0214
  80. https://www.researchgate.net/publication/51741731_Associations_between_unemployment_and_major_depressive_disorder_Evidence_from_an_international_prospective_study_the_predict_cohort
  81. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-018-1736-5
  82. https://academic.oup.com/aje/article/187/9/1871/4959638
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC12463265/
  84. https://www.tandfonline.com/doi/full/10.1080/17482631.2024.2321644
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC10076339/
  86. https://www.ncbi.nlm.nih.gov/books/NBK28257/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC2872125/
  88. https://doi.org/10.1016/j.biopsych.2007.03.017
  89. https://www.nature.com/articles/s41392-024-01738-y
  90. https://www.sciencedirect.com/science/article/pii/S0889159125002119
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC3741070/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC2740752/
  93. https://medicalxpress.com/news/2025-06-inflammatory-subtype-major-depression-paving.html
  94. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2020.00082/full
  95. https://academic.oup.com/ijnp/article/11/8/1169/696736
  96. https://www.ncbi.nlm.nih.gov/books/NBK554406/
  97. https://www.nature.com/articles/s41398-020-0842-6
  98. https://www.nature.com/articles/s41598-024-54370-9
  99. https://psychiatryonline.org/doi/10.1176/appi.ajp.161.11.1957
  100. https://www.sciencedirect.com/science/article/abs/pii/S0022395612003433
  101. https://www.sciencedirect.com/science/article/pii/S0165032708001754
  102. https://www.biologicalpsychiatryjournal.com/article/S0006-3223%2807%2900565-3/pdf
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC4277233/
  104. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2732873
  105. https://www.nature.com/articles/srep43105
  106. https://www.pnas.org/doi/10.1073/pnas.0812686106
  107. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2014.00017/full
  108. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/208045
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC7288775/
  110. https://www.nature.com/articles/npp2015158
  111. https://www.psychiatry.org/psychiatrists/practice/dsm
  112. https://icd.who.int/
  113. https://www.uptodate.com/contents/image?imageKey=PSYCH%252F89994
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC6971212/
  115. https://www.wjgnet.com/2220-3206/full/v12/i12/1335.htm
  116. https://onlinelibrary.wiley.com/doi/10.1002/da.22217
  117. https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Depression-Bereavement-Exclusion.pdf
  118. https://www.ncbi.nlm.nih.gov/books/NBK519712/
  119. https://www.psychiatry.org/File%2520Library/Psychiatrists/Practice/DSM/APA_DSM_Cultural-Concepts-in-DSM-5.pdf
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC11272311/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC5889494/
  122. https://www.psychiatrist.com/jcp/mini-international-neuropsychiatric-interview-mini/
  123. https://psychology-tools.com/test/young-mania-rating-scale
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC10484643/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC7376322/
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC11180629/
  127. https://www.aafp.org/pubs/afp/issues/2008/0315/p785.html
  128. https://emedicine.medscape.com/article/286759-treatment
  129. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC10924823/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC11468148/
  132. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-021-03220-3
  133. https://www.psychiatrist.com/pcc/critical-appraisal-treatments-bipolar-disorder/
  134. https://www.nejm.org/doi/full/10.1056/NEJMoa2302399
  135. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2836115
  136. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC5164879/
  138. https://pubmed.ncbi.nlm.nih.gov/23870719/
  139. https://psychiatryonline.org/doi/10.1176/appi.ajp.159.8.1354
  140. https://journals.lww.com/ebp/fulltext/2022/07000/does_cognitive_behavioral_therapy_reduce_the.15.aspx
  141. https://pubmed.ncbi.nlm.nih.gov/11074869/
  142. https://pmc.ncbi.nlm.nih.gov/articles/PMC4920261/
  143. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/207846
  144. https://pubmed.ncbi.nlm.nih.gov/12795572/
  145. https://pubmed.ncbi.nlm.nih.gov/28577590/
  146. https://pubmed.ncbi.nlm.nih.gov/24974307/
  147. https://www.sciencedirect.com/science/article/abs/pii/S016503271400411X
  148. https://www.researchgate.net/publication/264049721_Relapse_rates_after_psychotherapy_for_depression_-_Stable_long-term_effects_A_meta-analysis
  149. https://pubmed.ncbi.nlm.nih.gov/38355154/
  150. https://pubmed.ncbi.nlm.nih.gov/26978184/
  151. https://pubmed.ncbi.nlm.nih.gov/34439743/
  152. https://pubmed.ncbi.nlm.nih.gov/38048912/
  153. https://pubmed.ncbi.nlm.nih.gov/34607184/
  154. https://pubmed.ncbi.nlm.nih.gov/40705857/
  155. https://pubmed.ncbi.nlm.nih.gov/26478195/
  156. https://pubmed.ncbi.nlm.nih.gov/31383846/
  157. https://pubmed.ncbi.nlm.nih.gov/36928725/
  158. https://pubmed.ncbi.nlm.nih.gov/38219230/
  159. https://pubmed.ncbi.nlm.nih.gov/25689576/
  160. https://pubmed.ncbi.nlm.nih.gov/23922209/
  161. https://pubmed.ncbi.nlm.nih.gov/20488270/
  162. https://pmc.ncbi.nlm.nih.gov/articles/PMC2921250/
  163. https://pubmed.ncbi.nlm.nih.gov/22858215/
  164. https://www.who.int/news-room/fact-sheets/detail/depression
  165. https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder
  166. https://www.dynamed.com/condition/major-depressive-disorder-mdd
  167. https://www.sciencedirect.com/science/article/abs/pii/S0165032723010066
  168. https://www.merckmanuals.com/professional/pediatrics/psychiatric-disorders-in-children-and-adolescents/depressive-disorders-in-children-and-adolescents
  169. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00222-0/fulltext
  170. https://www.healthdata.org/research-analysis/gbd
  171. https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide
  172. https://pmc.ncbi.nlm.nih.gov/articles/PMC4478054/
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC8607160/
  174. https://pmc.ncbi.nlm.nih.gov/articles/PMC8385738/
  175. https://pmc.ncbi.nlm.nih.gov/articles/PMC8684627/
  176. https://pmc.ncbi.nlm.nih.gov/articles/PMC3928067/
  177. https://pmc.ncbi.nlm.nih.gov/articles/PMC5069819/
  178. https://pmc.ncbi.nlm.nih.gov/articles/PMC7910330/
  179. https://pmc.ncbi.nlm.nih.gov/articles/PMC7012622/
  180. https://pmc.ncbi.nlm.nih.gov/articles/PMC8123462/
  181. https://pmc.ncbi.nlm.nih.gov/articles/PMC9796491/
  182. https://pmc.ncbi.nlm.nih.gov/articles/PMC6447754/
  183. https://www.uptodate.com/contents/major-depressive-disorder-in-adults-approach-to-initial-management
  184. https://www.nature.com/articles/s41398-019-0460-3
  185. https://psychiatryonline.org/doi/10.1176/appi.focus.18205
  186. https://pubmed.ncbi.nlm.nih.gov/26238969/
  187. https://www.sciencedirect.com/science/article/pii/S0165032721012611
  188. https://psychiatryonline.org/doi/10.1176/appi.ajp.2017.17090972
  189. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.951008/full
  190. https://pubmed.ncbi.nlm.nih.gov/10708837/
  191. https://pmc.ncbi.nlm.nih.gov/articles/PMC10086173/
  192. https://pmc.ncbi.nlm.nih.gov/articles/PMC10141876/
  193. https://pmc.ncbi.nlm.nih.gov/articles/PMC2094705/
  194. https://lindnercenterofhope.org/wp-content/uploads/2014/06/2010-J-Aff-Disorders-Prevalence-and-correlates-of-eating-disorders-with-bipolar-disorder.pdf
  195. https://pmc.ncbi.nlm.nih.gov/articles/PMC3729346/
  196. https://pmc.ncbi.nlm.nih.gov/articles/PMC8960118/
  197. https://pubmed.ncbi.nlm.nih.gov/10073388/
  198. https://www.intechopen.com/chapters/1192722
  199. https://annals-general-psychiatry.biomedcentral.com/articles/10.1186/s12991-023-00487-6
  200. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/411551
  201. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.552532/full
  202. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2787198
  203. https://www.nature.com/articles/s41398-023-02522-2
  204. https://www.nimh.nih.gov/news/science-updates/2025
  205. https://www.bipolardiscoveries.org/2025/10/bd%25C2%25B2-awards-18-million-in-grants-to-advance-research-on-the-biology-of-bipolar-disorder/
  206. https://www.sciencedirect.com/science/article/abs/pii/S0925492723000653
  207. https://keck.usc.edu/news/a-new-global-study-aims-to-map-the-brain-signatures-of-bipolar-disorder-to-transform-understanding-of-the-disease/
  208. https://www.pharmacytimes.com/view/fda-breakthrough-therapy-designation-granted-to-novel-psychedelic-molecule-cyb003-for-major-depressive-disorder
  209. https://ir.cybin.com/investors/news/news-details/2024/Cybin-Reports-Positive-Phase-2-Data-for-CYB003-Demonstrating-Breakthrough-12-Month-Efficacy-in-Treating-Major-Depressive-Disorder/default.aspx
  210. https://www.nature.com/articles/s41591-023-02565-4
  211. https://icer.org/wp-content/uploads/2023/11/PTSD_Revised-Report_For-Publication_05142024.pdf
  212. https://mental.jmir.org/2017/2/e19/
  213. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1621768/epub
  214. https://www.sciencedirect.com/science/article/pii/S294988212300035X
  215. https://capmh.biomedcentral.com/articles/10.1186/s13034-023-00652-5
  216. https://doi.org/10.3390/brainsci15050489
  217. https://doi.org/10.4103/jpbs.jpbs_1765_24
  218. https://www.nature.com/articles/s41398-025-03497-y
Add your contribution
Related Hubs
User Avatar
No comments yet.